39 results
8-K
EX-99.1
KANT
Kineta, Inc.
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
research services provided under the Merck Neuromuscular License Agreement, which we completed in June 2023.
Research and development (R&D) expense: R … &D expenses were $2.7 million for the three months ended March 31, 2024 and $2.8 million for the three months ended March 31, 2023. The decrease in R&D expenses
8-K
EX-99.1
KANT
Kineta, Inc.
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
2022, and also due to services provided under a grant that was concluded in December 2022.
Research and development (R&D) expense: R&D expenses were … $9.0 million for the year ended December 31, 2023 and $15.9 million for the year ended December 31, 2022. The decreases in R&D expenses were primarily
8-K
EX-99.1
KANT
Kineta, Inc.
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
was terminated in December 2022.
Research and development (R&D) expense: R&D expenses were $1.9 million for the three months ended September 30, 2023 … to $10.5 million for the nine months ended September 30, 2022. The decreases in R&D expenses were primarily due to lower activities for KVA12123
8-K
EX-99.1
KANT
Kineta, Inc.
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
in December 2022.
Research and development (R&D) expense: R&D expenses were $2.7 million for the three months ended June 30, 2023 compared to $3.9 … ended June 30, 2022. The decreases in R&D expenses were primarily due to lower activities for KVA12123 manufacturing and clinical study start up
8-K
EX-99.1
KANT
Kineta, Inc.
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
expenses and capital expenditure requirements into early 2025.
Research and development (R&D) expense: R&D expenses were $2.8 million for the three … months ended March 31, 2023 compared to $4.0 million for the three months ended March 31, 2022. The decrease in R&D expenses was primarily due to lower
8-K
EX-99.1
51ukpq67l5
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.3
3io8o
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
425
zegksc nx
14 Nov 22
Business combination disclosure
8:50am
8-K
EX-99.1
cqljv3yi0jqnv
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
424B3
3oofh8 wjzr8rw31s
10 Nov 22
Prospectus supplement
4:21pm
8-K
EX-99.1
nx1xv
4 Aug 22
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
4:51pm
425
q7emnp
28 Jun 22
Business combination disclosure
4:03pm
8-K
EX-99.1
t4o1j
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.3
gh4k8wa nvl8fgqkvud
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
pk74zgrfvkxq 37ym
12 May 22
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
4:52pm